European guidelines on cardiovascular disease prevention in clinical practice: executive summary
暂无分享,去创建一个
D. Atar | G. Filippatos | A. Hoes | S. Priori | L. Ruilope | K. Mcgregor | J. Zamorano | S. Ebrahim | G. Boysen | I. Hellemans | K. Borch-Johnsen | S. Kjeldsen | R. Cífková | J. Dallongeville | J. Yarnell | P. Weissberg | C. Herrmann-Lingen | A. Zampelas | D. Wood | L. Tokgozoglu | Ž. Reiner | L. Rydén | M. Knapton | I. Graham | T. Fitzgerald | G. Burell | T. Pedersen | E. Walma | J. Perk | M. Cooney | A. Vahanian | A. Dudina | Stephen E. Humphries | B. Gjelsvik | M. Sammut | A. Manolis | R. Caterina | Petr Widimsky | G. D. Backer | G. Mancia | U. Sechtem | V. Dean | Olov Wiklund | R. Fagard | Kalevi Pyörälä | Kristina Orth-Gomér | Simona Giampaoli | P. N. Durrington | John Camm | Kenneth Dickstein | C. Funck-Brentano | S. D. Kristensen | S. Silber | Susana Sans-Menendez | Anton F. H. Stalenhoef | W. S. O. Reimer | Attila Altiner | E. Bonora | H. Hemingway | Jan Hakansson | Mogens Lytken Larsen | Mike Rayner | N. Schneiderman | M. Tendera | K. Pyörälä | K. Dickstein
[1] A. Dominiczak,et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.
[2] Ulf Risérus,et al. Sagittal abdominal diameter as a marker of inflammation and insulin resistance among immigrant women from the Middle East and native Swedish women: a cross-sectional study , 2007, Cardiovascular diabetology.
[3] D. Medeiros,et al. Dietary Reference Intakes: the Essential Guide to Nutrient Requirements edited by JJ Otten, JP Hellwig, and LD Meyers, 2006, 560 pages, hardcover, $44.96. The National Academies Press, Washington, DC. , 2007 .
[4] P. Poole‐Wilson,et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET) , 2007, Heart.
[5] D. Conrad,et al. Global variation in copy number in the human genome , 2006, Nature.
[6] C. Wiysonge,et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis , 2006, Journal of hypertension.
[7] Deborah F Tate,et al. A self-regulation program for maintenance of weight loss. , 2006, The New England journal of medicine.
[8] S. Humphries,et al. Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes , 2006, Journal of medical screening.
[9] A. Victor,et al. Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels – a study in twins , 2006, Genes and Immunity.
[10] Samuel Wann,et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ , 2006, European heart journal.
[11] T. Heise,et al. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients , 2006, Journal of hypertension.
[12] Alastair Gray,et al. Economic burden of cardiovascular diseases in the enlarged European Union. , 2006, European heart journal.
[13] G. Mancia,et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial , 2006, Journal of hypertension.
[14] Peter Lindgren,et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary , 2007 .
[15] A. Eckardstein. Differential diagnosis of familial high density lipoprotein deficiency syndromes. , 2006 .
[16] Andy McEwen,et al. Manual of Smoking Cessation , 2006 .
[17] G. Lowe,et al. Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture * , 2006, British journal of haematology.
[18] Raimund Erbel,et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.
[19] Mats Börjesson,et al. ESC Study Group of Sports Cardiology: recommendations for participation in leisure-time physical activity and competitive sports for patients with ischaemic heart disease , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[20] Silvia G Priori,et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. , 2006, European heart journal.
[21] L. Ruilope,et al. Chronic kidney disease as a situation of high added risk in hypertensive patients. , 2006, Journal of the American Society of Nephrology : JASN.
[22] S. Humphries,et al. Investigating the Genetic Determinants of Cardiovascular Disease Using Candidate Genes and Meta‐analysis of Association Studies , 2006, Annals of human genetics.
[23] Rodney A. White,et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography , 2006, Circulation.
[24] John Danesh,et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controls , 2006, The Lancet.
[25] Paul Poirier,et al. Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism , 2006, Circulation.
[26] M. Briel,et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. , 2006, Archives of internal medicine.
[27] Deepak L. Bhatt,et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.
[28] L. Smeeth,et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis , 2005, The Lancet.
[29] Jean-Claude Tardif,et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. , 2005, European heart journal.
[30] Oscar H Franco,et al. Effects of physical activity on life expectancy with cardiovascular disease. , 2005, Archives of internal medicine.
[31] T. Berl,et al. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. , 2005, Clinical journal of the American Society of Nephrology : CJASN.
[32] Lisa Hartling,et al. Meta-Analysis: Secondary Prevention Programs for Patients with Coronary Artery Disease , 2005, Annals of Internal Medicine.
[33] L. Lindholm,et al. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis , 2005, The Lancet.
[34] E. Braunwald,et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. , 2005, Journal of the American College of Cardiology.
[35] Ž. Reiner,et al. Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease. , 2005, The American journal of cardiology.
[36] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[37] M. Khoury,et al. How many genes underlie the occurrence of common complex diseases in the population? , 2005, International journal of epidemiology.
[38] Paul Zimmet,et al. The metabolic syndrome—a new worldwide definition , 2005, The Lancet.
[39] R. Collins,et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.
[40] L. Peltonen,et al. USF1 and dyslipidemias: converging evidence for a functional intronic variant. , 2005, Human molecular genetics.
[41] L. Getz,et al. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study , 2005, BMJ : British Medical Journal.
[42] D. Brancaccio,et al. Pathogenesis of vascular calcification in chronic kidney disease. , 2005, Kidney international.
[43] S. Priori,et al. Gender-specific prescription for cardiovascular diseases? , 2005, European heart journal.
[44] G. Lowe. Circulating inflammatory markers and risks of cardiovascular and non‐cardiovascular disease , 2005, Journal of thrombosis and haemostasis : JTH.
[45] S. Humphries,et al. Implementation of cascade testing for the detection of familial hypercholesterolaemia , 2005, Current opinion in lipidology.
[46] M. Goldacre,et al. Trends in mortality and hospital admission rates for abdominal aortic aneurysm in England and Wales, 1979–1999 , 2005, The British journal of surgery.
[47] Jackie A Cooper,et al. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. , 2005, Atherosclerosis.
[48] K. Berge,et al. Identification of deletions and duplications in the low density lipoprotein receptor gene by MLPA. , 2005, Clinica chimica acta; international journal of clinical chemistry.
[49] Jean-Claude Tardif,et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. , 2005, European heart journal.
[50] R. Coleman,et al. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. , 2005, JAMA.
[51] Thierry Troosters,et al. How to assess physical activity? How to assess physical fitness? , 2005, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[52] Karina W Davidson,et al. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. , 2005, Journal of the American College of Cardiology.
[53] Ž. Reiner,et al. [Concomitant use of statins and cytochrome P 450 inhibitors in Croatia]. , 2005, Liječnički vjesnik.
[54] L. Melvin,et al. Effects of estrogen with and without progestin on urinary incontinence , 2005, Journal of Family Planning and Reproductive Health Care.
[55] A. Geelen,et al. Effects of n-3 fatty acids from fish on premature ventricular complexes and heart rate in humans. , 2005, The American journal of clinical nutrition.
[56] E. Lewis,et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[57] A. Bikhazi,et al. Effect of insulin and angiotensin II receptor subtype-1 antagonist on myocardial remodelling in rats with insulin-dependent diabetes mellitus , 2005, Journal of hypertension.
[58] G. Mancia,et al. Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection , 2005, Blood pressure.
[59] R. Hubbard,et al. Risk of myocardial infarction and stroke after acute infection or vaccination. , 2004, The New England journal of medicine.
[60] J. Craig,et al. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. , 2004, Journal of the American Society of Nephrology : JASN.
[61] G. Remuzzi,et al. Preventing microalbuminuria in type 2 diabetes. , 2004, The New England journal of medicine.
[62] David B Allison,et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. , 2004, Circulation.
[63] M. Tonelli,et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. , 2004, Journal of the American College of Cardiology.
[64] M. Pfeffer,et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.
[65] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[66] F. Magrini,et al. Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis: Results of a Randomized Trial , 2004, Circulation.
[67] D. Bacquer,et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys , 2004, Diabetologia.
[68] G. Guyatt,et al. Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.
[69] Ž. Reiner,et al. Atherosclerosis of retinal arteries in men: role of serum lipoproteins and apoproteins. , 2004, Croatian medical journal.
[70] P. Sweetnam,et al. Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies. , 2004, European heart journal.
[71] J. Brunzell,et al. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. , 2004, The Journal of clinical endocrinology and metabolism.
[72] Gösta Samuelson,et al. Global strategy on diet, physical activity and health , 2004 .
[73] S. Ebrahim,et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. , 2004, The American journal of medicine.
[74] Vilmundur Gudnason,et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.
[75] Philippa J Talmud,et al. Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation? , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[76] Paul Schoenhagen,et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.
[77] L. Peltonen,et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1) , 2004, Nature Genetics.
[78] Daniel Levy,et al. Predictors of new-onset kidney disease in a community-based population. , 2004, JAMA.
[79] Constance K Haan,et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women , 2004, Circulation.
[80] C. Herrmann-Lingen,et al. Screening for psychosocial risk factors in patients with coronary heart disease-recommendations for clinical practice , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[81] T. Leren,et al. Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program. , 2004, Seminars in vascular medicine.
[82] F. Civeira,et al. Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. , 2004, Seminars in vascular medicine.
[83] K. Eagle,et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. , 2004, Journal of vascular surgery.
[84] Claude Lenfant,et al. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[85] S. Blankenberg,et al. Interleukin-18 and the Risk of Coronary Heart Disease in European Men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) , 2003, Circulation.
[86] F. Turnbull. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.
[87] S. Yusuf,et al. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[88] K. Fox,et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.
[89] H. Diener,et al. European Stroke Initiative Recommendations for Stroke Management – Update 2003 , 2003, Cerebrovascular Diseases.
[90] G. Mancia,et al. European guidelines on cardiovascular disease prevention in clinical practice; Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) , 2003, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[91] W. Ambrosius,et al. Older adults with chronic disease: benefits of group-mediated counseling in the promotion of physically active lifestyles. , 2003, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.
[92] R. Schmieder,et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. , 2003, The American journal of medicine.
[93] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[94] Peter W de Leeuw,et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. , 2003, The New England journal of medicine.
[95] J. Weissenbach,et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.
[96] R. Pandey,et al. Non-obese (body mass index < 25 kg/m2) Asian Indians with normal waist circumference have high cardiovascular risk. , 2003, Nutrition.
[97] H. Tunstall-Pedoe,et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.
[98] E. Hawe,et al. Family History is a Coronary Heart Disease Risk Factor in the Second Northwick Park Heart Study , 2003, Annals of human genetics.
[99] V. Gudnason,et al. Systematic Family Screening for Familial Hypercholesterolemia in Iceland , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[100] Yu-ling,et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.
[101] R. Collins,et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.
[102] RAP Scott,et al. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial , 2002, The Lancet.
[103] G. Mancia,et al. Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial , 2002, Circulation.
[104] H. Arnesen,et al. Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.
[105] M. Nieminen,et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study , 2002, Journal of hypertension.
[106] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[107] N. Martin,et al. Heritabilities of apolipoprotein and lipid levels in three countries. , 2002, Twin research : the official journal of the International Society for Twin Studies.
[108] M. Nieminen,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[109] P. Libby,et al. Inflammation and Atherosclerosis , 2002, Circulation.
[110] A. Connor,et al. The way I see it: House officers need formal career development , 2002 .
[111] P. Mehler,et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. , 2002, Kidney international.
[112] G. Assmann,et al. Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study , 2002, Circulation.
[113] R. Peto,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[114] Daniel Levy,et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study , 2001, The Lancet.
[115] J. Kastelein,et al. The molecular basis of familial hypercholesterolemia in The Netherlands , 2001, Human Genetics.
[116] G. Norman,et al. Self-efficacy, psychosocial factors, and exercise behavior in traditional versus modified cardiac rehabilitation. , 2001, Journal of cardiopulmonary rehabilitation.
[117] P. Armstrong,et al. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review , 2001, BMJ : British Medical Journal.
[118] M. Woodward,et al. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .
[119] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[120] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[121] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.
[122] Michael F. Oliver,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.
[123] Lawrence Joseph,et al. β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis , 2001 .
[124] S. Humphries,et al. A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom , 2001, European Journal of Human Genetics.
[125] D. Wood,et al. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001, The Lancet.
[126] N. Chaturvedi. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. , 2001, Annals of internal medicine.
[127] J. Pankow,et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. , 2001, Atherosclerosis.
[128] J. Porter,et al. The American Association for Vascular Surgery. , 2001, Cardiovascular surgery.
[129] T. Pischon,et al. Hypothesis: β-Adrenergic Receptor Blockers and Weight Gain , 2001 .
[130] E. Sijbrands,et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands , 2001, The Lancet.
[131] G. Bray,et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet , 2001 .
[132] B. Wajchenberg. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. , 2000, Endocrine reviews.
[133] A. Astrup,et al. Obesity : Preventing and managing the global epidemic , 2000 .
[134] B. Conrad,et al. Relationship Between Circadian Blood Pressure Patterns and Progression of Early Carotid Atherosclerosis: A 3-Year Follow-Up Study , 2000, Circulation.
[135] J. Danesh,et al. Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.
[136] T. Sellers,et al. Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study. , 2000, Archives of internal medicine.
[137] P. Ridker,et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.
[138] Eduard Diogène,et al. β-Adrenergic Blocking Agents in Heart Failure: Benefits of Vasodilating and Nonvasodilating Agents According to Patients' Characteristics: A Meta-analysis of Clinical Trials , 2000 .
[139] Karla Kerlikowske,et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials , 2000, The Lancet.
[140] E. Vartiainen,et al. Cardiovascular risk factor changes in Finland, 1972-1997. , 2000, International journal of epidemiology.
[141] Bruce H. R. Wolffenbuttel,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.
[142] S. Yusuf,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[143] J. Martínez,et al. Physical inactivity, sedentary lifestyle and obesity in the European Union , 1999, International Journal of Obesity.
[144] M. Awerbuch. Non-specific arm pain , 1999, The Lancet.
[145] I. Jialal,et al. GISSI-Prevenzione trial , 1999, The Lancet.
[146] J. Meulman,et al. A meta-analysis of psychoeducational programs for coronary heart disease patients. , 1999 .
[147] M. Burnier,et al. Compliance with antihypertensive therapy. , 1999, Clinical and experimental hypertension.
[148] Nick Freemantle,et al. β Blockade after myocardial infarction: systematic review and meta regression analysis , 1999 .
[149] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[150] L. Smeeth,et al. Numbers needed to treat derived from meta-analyses—sometimes informative, usually misleading , 1999, BMJ.
[151] K. McDonald,et al. Meta-analysis of Trials Comparing β-Blockers, Calcium Antagonists, and Nitrates for Stable Angina , 1999 .
[152] H. Tunstall-Pedoe,et al. Contribution of trends in survival and coronar y-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations , 1999, The Lancet.
[153] G. Lowe,et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. , 1999, European heart journal.
[154] P. Brocklehurst. Infection and preterm delivery , 1999, BMJ.
[155] J. Grimshaw,et al. Potential benefits, limitations, and harms of clinical guidelines , 1999, BMJ.
[156] W A Kalender,et al. Electrocardiogram-correlated image reconstruction from subsecond spiral computed tomography scans of the heart. , 1998, Medical physics.
[157] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[158] A. Zanchetti,et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long‐term randomized treatment with either verapamil or chlorthalidone on carotid intima‐media thickness , 1998, Journal of hypertension.
[159] G. Mancia,et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.
[160] Ian Graham,et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. , 1998, European heart journal.
[161] A. Jacobs,et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI) , 1998, Circulation.
[162] Siep Thomas,et al. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study , 1998, BMJ.
[163] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[164] Jenny Field,et al. General practitioners' perceptions of the route to evidence based medicine: a questionnaire survey , 1998, BMJ.
[165] G. Guyatt,et al. Effect of HMGcoA Reductase Inhibitors on Stroke , 1998, Annals of Internal Medicine.
[166] G. Smith,et al. Meta-analysis Spurious precision? Meta-analysis of observational studies , 1998, BMJ.
[167] N J Wald,et al. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence , 1997, BMJ.
[168] H. Levine. Rest heart rate and life expectancy. , 1997, Journal of the American College of Cardiology.
[169] Roberto Sega,et al. Blood-pressure control in the hypertensive population , 1997, The Lancet.
[170] M. Rocco,et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. , 1996, JAMA.
[171] W. Kannel. Blood pressure as a cardiovascular risk factor: prevention and treatment. , 1996, JAMA.
[172] R. Vasan,et al. The progression from hypertension to congestive heart failure. , 1996, JAMA.
[173] B. Lernfelt,et al. 15-year longitudinal study of blood pressure and dementia , 1996, The Lancet.
[174] W. Linden,et al. Psychosocial interventions for patients with coronary artery disease: a meta-analysis. , 1996 .
[175] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[176] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[177] R. Raiteri,et al. Anthropometric or ultrasonic measurements in assessment of visceral fat? A comparative study. , 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[178] P. Poole‐Wilson,et al. Prevention of coronary heart disease in clinical practice , 1994 .
[179] P. Poole‐Wilson,et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. , 1994, European heart journal.
[180] E. Vartiainen,et al. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland , 1994, BMJ.
[181] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.
[182] M Alpsten,et al. A multicompartment body composition technique based on computerized tomography. , 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[183] A Tremblay,et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. , 1994, The American journal of cardiology.
[184] M. Egger,et al. Who benefits from medical interventions? , 1994, BMJ.
[185] N. B. Myant. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. , 1993, Atherosclerosis.
[186] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[187] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .
[188] K. Caidahl,et al. Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. CONSENSUS II Multi-Echo Study Group. , 1993, The American journal of cardiology.
[189] G Mancia,et al. Prognostic value of 24-hour blood pressure variability , 1993, Journal of hypertension.
[190] M. Leppert,et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. , 1993, The American journal of cardiology.
[191] P. Macfarlane,et al. Heart rate, ischaemic heart disease, and sudden cardiac death in middle-aged British men. , 1993, British heart journal.
[192] R S Paffenbarger,et al. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. , 1993, The New England journal of medicine.
[193] David Lee Gordon,et al. Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.
[194] R. Neuwirth,et al. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. , 1992, JAMA.
[195] R. Krauss,et al. Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes. , 1992, American Journal of Human Genetics.
[196] R Guardo,et al. Quantification of adipose tissue by MRI: relationship with anthropometric variables. , 1992, Journal of applied physiology.
[197] J. Samet. Health benefits of smoking cessation. , 1991, Clinics in Chest Medicine.
[198] W. Kannel,et al. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. , 1990, American heart journal.
[199] C. Procacci,et al. The contribution of sonography to the measurement of intra‐abdominal fat , 1990, Journal of clinical ultrasound : JCU.
[200] A Tremblay,et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. , 1990, Arteriosclerosis.
[201] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.
[202] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.
[203] L. Sjöström,et al. Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations. , 1988, The American journal of clinical nutrition.
[204] G. Assmann,et al. The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. , 1988, American heart journal.
[205] R S Paffenbarger,et al. Heart rate and cardiovascular mortality: the Framingham Study. , 1987, American heart journal.
[206] G Parati,et al. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. , 1987, Journal of hypertension.
[207] J. Kjekshus,et al. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. , 1986, The American journal of cardiology.
[208] C. Zarins,et al. Retarding effect of lowered heart rate on coronary atherosclerosis. , 1984, Science.
[209] P. Björntorp,et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. , 1984, British medical journal.
[210] G. Rose,et al. Strategy of prevention: lessons from cardiovascular disease. , 1981, British medical journal.
[211] A. Motulsky,et al. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. , 1973, The Journal of clinical investigation.
[212] D. Patterson,et al. Lipid abnormalities in male and female survivors of myocardial infarction and their first-degree relatives. , 1972, Lancet.
[213] S. Allender,et al. European cardiovascular disease statistics , 2008 .
[214] J. Barth,et al. Smoking Cessation in Patients With Coronary Heart Disease: Risk Reduction and an Evaluation of the Efficacy of Interventions. , 2007 .
[215] W. J. Howard. Low-Fat Dietary Pattern and Risk of Cardiovascular Disease: The Women's Health Initiative Randomized Controlled Dietary Modification Trial , 2007 .
[216] D. Kromhout,et al. Dynamics of cardiovascular and all-cause mortality in Western and Eastern Europe between 1970 and 2000. , 2006, European heart journal.
[217] G. Bakris,et al. Cardiometabolic syndrome and chronic kidney disease: what is the link? , 2006, Journal of the cardiometabolic syndrome.
[218] G. Mancia,et al. New-onset diabetes and antihypertensive drugs. , 2006, Journal of Hypertension.
[219] S. Moebus,et al. Prevalence of Peripheral Arterial Disease – Results of the Heinz Nixdorf Recall Study , 2006, European Journal of Epidemiology.
[220] A. Evans,et al. Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study. , 2003, Atherosclerosis.
[221] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[222] S E Humphries,et al. Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis. , 2001, Atherosclerosis.
[223] G. Lowe,et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease , 1999 .
[224] Claude Bouchard,et al. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: Executive summary , 1998 .
[225] L. Wilhelmsen,et al. Physical activity protects against coronary death and deaths from all causes in middle-aged men. Evidence from a 20-year follow-up of the primary prevention study in Göteborg. , 1997, Annals of epidemiology.
[226] Philippe Amouyel,et al. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. , 1997 .
[227] R. Collins,et al. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. , 1994, British medical bulletin.
[228] T. Manolio,et al. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. , 1992, Annals of epidemiology.
[229] K. Anderson,et al. An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.